CN113476463A - Prebiotic composition and application thereof - Google Patents
Prebiotic composition and application thereof Download PDFInfo
- Publication number
- CN113476463A CN113476463A CN202110792547.XA CN202110792547A CN113476463A CN 113476463 A CN113476463 A CN 113476463A CN 202110792547 A CN202110792547 A CN 202110792547A CN 113476463 A CN113476463 A CN 113476463A
- Authority
- CN
- China
- Prior art keywords
- prebiotic composition
- oligosaccharide
- products
- prebiotic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 79
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 57
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 57
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 48
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 48
- 210000002966 serum Anatomy 0.000 claims abstract description 35
- 201000010063 epididymitis Diseases 0.000 claims abstract description 23
- 208000008589 Obesity Diseases 0.000 claims abstract description 21
- 235000020824 obesity Nutrition 0.000 claims abstract description 21
- 230000004584 weight gain Effects 0.000 claims abstract description 21
- 235000019786 weight gain Nutrition 0.000 claims abstract description 21
- 230000001603 reducing effect Effects 0.000 claims abstract description 20
- 229930182843 D-Lactic acid Natural products 0.000 claims abstract description 19
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims abstract description 19
- 229940022769 d- lactic acid Drugs 0.000 claims abstract description 19
- 239000002158 endotoxin Substances 0.000 claims abstract description 19
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 25
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 239000013585 weight reducing agent Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 11
- 210000000918 epididymis Anatomy 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a prebiotic composition and application thereof, belonging to the technical field of biology. The prebiotic composition comprises fructo-oligosaccharide and galacto-oligosaccharide, and the invention also provides a preparation method and application of the prebiotic composition. The prebiotic composition obtained by the preparation method can be used for preparing products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing weight gain, products for reducing epididymal fat and products for emerging micro-ecological medical treatment fields, can effectively avoid the side effect of drug weight reduction, accurately play the physiological effect of the prebiotic composition, overcome the limitations of ambiguity, randomness and the like of prebiotic application level, provide typical demonstration for the application of accurate nutrition, emerging micro-ecological medical treatment and other biological medicine fields, and is beneficial to improving the prevention control and treatment rehabilitation of obesity.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a prebiotic composition and application thereof.
Background
Obesity is a chronic, complex disease, and is closely related to diseases such as hyperlipidemia, type 2 diabetes, fatty liver, cardiovascular diseases, cancer, etc. which are common in the present society. Excessive accumulation of fat can have adverse effects on the metabolism, physiological activities and mental health of the body. Therefore, weight loss and prevention of obesity are important areas of research in the management of many chronic diseases.
For a long time, prevention and treatment means for obesity have been sought. Orlistat (Orlistat), which is the current relatively popular weight loss product, was approved in europe in 1998 and is the only FDA approved drug for long-term obesity treatment that inhibits gastrointestinal and pancreatic lipases, blocks hydrolysis of triglycerides, and reduces absorption of ingested fat. However, while reducing body weight, there are some inevitable side effects such as fecal incontinence, excessive defecation, oily stool, etc., fat-soluble vitamins need to be supplemented to avoid vitamin deficiency, and intestinal microbial diversity and abundance are also reduced.
To avoid the side effects of drug weight loss, it is considered to control obesity by another means. Prebiotics are a class of substances that are selectively utilized by microorganisms to confer a health benefit on the host, including Fructooligosaccharides (FOS), Galactooligosaccharides (GOS), and the like. Regular intake of prebiotics such as fructo-oligosaccharide and galacto-oligosaccharide can increase short chain fatty acids produced by intestinal flora and increase release of peptides for eliminating fat.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a prebiotic composition which can be used for preparing products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing weight gain, products for reducing epididymal fat and products for emerging microecological medical field.
In order to achieve the purpose, the invention adopts the technical scheme that: a prebiotic composition comprising a fructooligosaccharide and a galactooligosaccharide.
The prebiotic composition obtained by the technical scheme of the invention can be used for preparing products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing weight gain, products for reducing epididymal fat and products for the field of emerging micro-ecological medical treatment, can effectively avoid the side effect of drug weight loss, accurately play the physiological action of the prebiotic composition, overcome the limitations of ambiguity, randomness and the like of the prebiotic application level, provide typical demonstration for the application of the fields of biomedicine such as accurate nutrition and emerging micro-ecological medical treatment and the like, and is beneficial to improving the prevention control and treatment rehabilitation of obesity.
In a preferred embodiment of the prebiotic composition of the present invention, the fructooligosaccharide is 100 to 900 parts by mass, and the galactooligosaccharide is 100 to 900 parts by mass.
In a preferred embodiment of the prebiotic composition of the present invention, the fructooligosaccharide is 300 to 900 parts by mass, and the galactooligosaccharide is 100 to 700 parts by mass.
In a preferred embodiment of the prebiotic composition of the present invention, the fructooligosaccharide is 500 to 900 parts by mass, and the galactooligosaccharide is 100 to 500 parts by mass.
In a preferred embodiment of the prebiotic composition of the present invention, the fructooligosaccharide is 700 to 900 parts by mass, and the galactooligosaccharide is 100 to 300 parts by mass.
The fructo-oligosaccharide is a natural active substance, can bidirectionally regulate the micro-ecological balance of a human body, and is a typical super-strong bifidus factor; the galactooligosaccharide is a nutrient source and an effective proliferation factor of beneficial bacteria such as bifidobacterium, acidophilic lactobacillus and the like in human intestinal tracts, and can improve the digestion and absorption functions of the human intestinal tracts. The invention can achieve the effect which cannot be achieved by single use by matching fructo-oligosaccharide and galacto-oligosaccharide. The preference for the ratio is mainly based on the combined reducing effect of the prebiotic composition on the individual obesity indicators. Wherein, the prebiotic composition with the mass part of the fructo-oligosaccharide of 900 parts and the mass part of the galacto-oligosaccharide of 100 parts has the best comprehensive reduction effect on each obesity index.
In addition, the invention also provides application of the prebiotic composition in preparing products for improving obesity.
In addition, the invention also provides application of the prebiotic composition in preparing products for reducing serum lipopolysaccharide and serum D-lactic acid.
In addition, the invention also provides application of the prebiotic composition in preparing products for reducing weight gain.
In addition, the invention also provides application of the prebiotic composition in preparation of products for reducing epididymis fat.
In addition, the invention also provides application of the prebiotic composition in preparation of products used in the emerging field of microecological medical treatment.
Compared with the prior art, the invention has the beneficial effects that: the invention provides a prebiotic composition comprising fructooligosaccharides and galactooligosaccharides. Meanwhile, the invention also provides application of the prebiotic composition in preparing products for improving obesity, products for reducing serum lipopolysaccharide and serum D-lactic acid, products for reducing weight gain, products for reducing epididymal fat and products for emerging micro-ecological medical field. The prebiotic composition obtained by the technical scheme of the invention can effectively improve obesity index, avoid side effect of drug weight loss, accurately exert physiological effect of the prebiotic composition, overcome the limitations of ambiguity, randomness and the like of prebiotic application level, provide typical demonstration for application in the biomedical fields of accurate nutrition, emerging micro-ecological medical treatment and the like, and is beneficial to improvement of prevention control and treatment rehabilitation of obesity.
Drawings
FIG. 1 is a graph of the effect of prebiotic compositions of example 6 on weight gain in an obese mouse model;
FIG. 2 is a graph of the effect of prebiotic compositions of example 6 on epididymal fat index in an obese mouse model;
FIG. 3 is a graph of the effect of prebiotic compositions of example 6 on Lee index in an obese mouse model;
FIG. 4 is a graph of the effect of prebiotic compositions of example 6 on serum lipopolysaccharide content in a mouse model of obesity;
FIG. 5 is a graph of the effect of prebiotic compositions of example 6 on serum D-lactic acid levels in obese mouse models.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
The prebiotic composition provided by the embodiment of the invention comprises the following components in percentage by mass: 900 parts of fructo-oligosaccharide and 100 parts of galacto-oligosaccharide.
The prebiotic composition described in this example was prepared as follows:
taking 900g of fructo-oligosaccharide and 100g of galacto-oligosaccharide, sieving the two, uniformly mixing, adding normal saline to dissolve the mixture until the concentration is 75 percent, and finally sterilizing to obtain the prebiotic composition 1.
Example 2
The prebiotic composition provided by the embodiment of the invention comprises the following components in percentage by mass: 700 parts of fructo-oligosaccharide and 300 parts of galacto-oligosaccharide.
The prebiotic composition described in this example was prepared as follows:
taking 700g of fructo-oligosaccharide and 300g of galacto-oligosaccharide, sieving the two, uniformly mixing, adding physiological saline to dissolve the mixture until the concentration is 75 percent, and finally sterilizing to obtain the prebiotic composition 2.
Example 3
The prebiotic composition provided by the embodiment of the invention comprises the following components in percentage by mass: 500 parts of fructo-oligosaccharide and 500 parts of galacto-oligosaccharide.
The prebiotic composition described in this example was prepared as follows:
taking 500g of fructo-oligosaccharide and 500g of galacto-oligosaccharide, sieving the two, uniformly mixing, adding normal saline to dissolve the mixture until the concentration is 75 percent, and finally sterilizing to obtain the prebiotic composition 3.
Example 4
The prebiotic composition provided by the embodiment of the invention comprises the following components in percentage by mass: 300 parts of fructo-oligosaccharide and 700 parts of galacto-oligosaccharide.
The prebiotic composition described in this example was prepared as follows:
taking 300g of fructo-oligosaccharide and 700g of galacto-oligosaccharide, sieving the two, uniformly mixing, adding normal saline to dissolve the mixture until the concentration is 75 percent, and finally sterilizing to obtain the prebiotic composition 4.
Example 5
The prebiotic composition provided by the embodiment of the invention comprises the following components in percentage by mass: 100 parts of fructo-oligosaccharide and 900 parts of galacto-oligosaccharide.
The prebiotic composition described in this example was prepared as follows:
taking 100g of fructo-oligosaccharide and 900g of galacto-oligosaccharide, sieving the two, uniformly mixing, adding normal saline to dissolve the mixture until the concentration is 75 percent, and finally sterilizing to obtain the prebiotic composition 5.
Comparative example 1
Comparative example 1 was the preparation of fructooligosaccharides.
The preparation method of the fructo-oligosaccharide of the comparative example is as follows:
1000g of fructo-oligosaccharide is taken, sieved and dissolved by adding normal saline with the concentration of 75 percent, and finally, the fructo-oligosaccharide is obtained by sterilization.
Comparative example 2
Comparative example 2 was the preparation of galactooligosaccharides.
The preparation method of galactooligosaccharide described in this comparative example is as follows:
1000g of galacto-oligosaccharide is taken, sieved and dissolved by adding normal saline with the concentration of 75 percent, and finally, the galacto-oligosaccharide is obtained by sterilization.
Example 6
The embodiment of the invention researches the application of the prebiotic composition in preparing products for improving obesity, which comprises the following contents:
(1) establishing a mouse model: 80 mice with 5-week-old males, the average weight of 22 +/-2 g and the SPF grade of C57BL/6 are taken, after one week of ordinary feed feeding, the 80 mice are randomly divided into 8 groups, each group comprises 10 mice, the normal group (N) is fed with the ordinary feed, and the other groups are fed with 60% high-fat feed. Mice of the normal group (N) and the model group (M) were gavaged with 0.2mL of physiological saline daily, the positive control group (Y) was gavaged with orlistat physiological saline at a dose of 120mg/kg/d, the fructooligosaccharide of comparative example 1 was gavaged with 1.7g/kg/d for the fructooligosaccharide low dose group (FL), the fructooligosaccharide of comparative example 1 was gavaged with 8.5g/kg/d for the fructooligosaccharide high dose group (FH), the galactooligosaccharide of comparative example 2 was gavaged with 1.7g/kg/d for the galactooligosaccharide low dose Group (GL), the galactooligosaccharide of comparative example 2 was gavaged with 8.5g/kg/d for the galactooligosaccharide of comparative example 2, and the prebiotic composition of examples 1-5 was gavaged with 8.5g/kg/d for the prebiotic composition of 1-5 (S), the gavage treatment time was 6 weeks.
(2) Calculation of weight gain: the weight gain of mice was calculated from these two data and the results of the weight gain were shown in table 1, wherein the weight gain of the composition 1 obtained in example 1 was the least increased in weight, and the normal group, model group, positive control group, low-dose group of fructo-oligosaccharide, high-dose group of fructo-oligosaccharide, low-dose group of galacto-oligosaccharide, and high-dose group of galacto-oligosaccharide were plotted in a bar graph, as shown in fig. 1.
As can be seen from fig. 1, the weight gain of the mice of the prebiotic composition group (S) and the positive control group (Y) remained equal, and both of them significantly reduced the weight gain of the model group mice; the weight gain of the low-dose group of Fructooligosaccharides (FL) was greater than that of the high-dose group of Fructooligosaccharides (FH) and the weight gain of the low-dose group of Galactooligosaccharides (GL) was less than that of the high-dose group of Galactooligosaccharides (GH), indicating that it is not a simple dose-dependent relationship that either fructooligosaccharides or galactooligosaccharides alone reduce the weight gain of mice.
(3) Calculating the epididymis index: after the mice were sacrificed, the intact epididymal fat was removed, the epididymal index was calculated according to the formula of epididymal fat index (g)/body weight (g), the obtained result of the epididymal index is shown in table 1, and the composition 1 obtained in example 1, in which the epididymal index was the smallest, was plotted as a histogram with the normal group, the model group, the positive control group, the low-dose group of fructooligosaccharide, the high-dose group of fructooligosaccharide, the low-dose group of galactooligosaccharide, and the high-dose group of galactooligosaccharide, as shown in fig. 2.
As can be seen from fig. 2, the fat index of the epididymis of the prebiotic composition group (S) is kept equal to the fat index of the epididymis of the positive control group (Y), and both of them can significantly reduce the fat index of the epididymis of the mice of the model group; the effect of the low-dose fructo-oligosaccharide (FL) and low-dose galacto-oligosaccharide (GL) on the reduction of epididymal fat index in mice was superior to that of the high-dose fructo-oligosaccharide (FH) and high-dose galacto-oligosaccharide (GH), indicating that the epididymal fat index was not decreased with increasing dose of fructo-oligosaccharide or galacto-oligosaccharide.
(4) Calculation of Lee index: at the end of the experiment, the mouse mass and body length were measured, and the Lee index was calculated according to the Lee index ═ body mass (g) ^ (1/3) × 1000/body length (cm), and the Lee index results obtained are shown in table 1, and composition 1 obtained in example 1, in which the Lee index was the smallest, and normal group, model group, positive control group, low-dose group of fructooligosaccharide, high-dose group of fructooligosaccharide, low-dose group of galactooligosaccharide, and high-dose group of galactooligosaccharide were plotted as a bar graph, as shown in fig. 3.
As can be seen from fig. 3, the Lee index of the mice of prebiotic composition group (S) remained equal to that of the positive control group (Y), and both significantly decreased the Lee index of the mice of the model group; the effect of the low-dose group of Fructooligosaccharides (FL) and the low-dose group of Galactooligosaccharides (GL) on the reduction of the mouse Lee index was slightly better than the effect of the high-dose group of Fructooligosaccharides (FH) and the high-dose group of Galactooligosaccharides (GH) on the reduction of the mouse Lee index.
(5) Measurement of serum lipopolysaccharide and serum D-lactic acid content: after a mouse is fasted for 12 hours, the eyeball is picked up and blood is collected, the mouse is kept stand for 60 minutes at room temperature and centrifuged for 15 minutes at 3000rpm, serum is sucked and placed in a small test tube, the contents of lipopolysaccharide and D-lactic acid in the supernatant are detected by an enzyme-linked immunosorbent assay, the obtained results of the contents of the lipopolysaccharide and the D-lactic acid in the serum are shown in table 1, the composition 1 obtained in the example 1 with the minimum content of the lipopolysaccharide and the D-lactic acid in the serum in the composition, a normal group, a model group, a positive control group, a low-dose fructooligosaccharide group, a high-dose fructooligosaccharide group, a low-dose galactooligosaccharide group and a high-dose galactooligosaccharide group are drawn into a column diagram, the content of the lipopolysaccharide in the serum is shown in figure 4, and the content of the D-lactic acid in the serum is shown in figure 5.
As can be seen from FIGS. 4 and 5, the prebiotic composition (S) has a certain effect of reducing serum lipopolysaccharide and serum D-lactic acid, and can significantly reduce the contents of serum lipopolysaccharide and serum D-lactic acid in the model mice.
Table 1: prebiotic composition Experimental data sheet
As can be seen from table 1, the prebiotic composition can significantly reduce the weight gain of the model group mice, reduce the epididymis index and Lee index of the model group mice, and reduce the content of serum lipopolysaccharide and serum D-lactic acid in the model group mice, and the reduction range of the prebiotic composition on the weight gain, the epididymis index, the Lee index, the serum lipopolysaccharide content and the serum D-lactic acid content is related to the weight parts of fructooligosaccharide and galactooligosaccharide in the prebiotic composition, and the data in table 1 shows that the reduction range of the prebiotic composition 1 to prebiotic composition 5 prepared in examples 1 to 5 on the whole is the greatest when 900 parts of fructooligosaccharide and 100 parts of galactooligosaccharide are used. Therefore, the experimental data of prebiotic composition 1 was further selected and plotted as bar graphs 1-5 with the experimental data of normal group, model group, positive control group, low-dosage group of fructooligosaccharide, high-dosage group of fructooligosaccharide, low-dosage group of galactooligosaccharide, and high-dosage group of galactooligosaccharide.
As can be seen from fig. 1 to 5, overall, the effect of the prebiotic composition group (S) on the weight gain, the epididymis index, the Lee index, the serum lipopolysaccharide content and the serum D-lactic acid content is almost equal to that of the positive control group (Y), and both of them can significantly reduce the weight gain, the epididymis index, the Lee index, the serum lipopolysaccharide content and the serum D-lactic acid content of the model group mice; meanwhile, the fructo-oligosaccharide low-dose group (FL), the galacto-oligosaccharide low-dose Group (GL), the fructo-oligosaccharide high-dose group (FH) and the galacto-oligosaccharide high-dose Group (GH) have certain effects on the weight gain, epididymis index, Lee index, serum lipopolysaccharide content and serum D-lactic acid content of the mice in the model group, but the effects are evaluated on the whole, and the effects are not good in the reduction effect of the prebiotic composition group (S) on each index. The results indicate that the fructo-oligosaccharide and the galacto-oligosaccharide have certain effect of improving the obesity index, but the overall effect is not superior to the effect of the prebiotic composition on improving the obesity index.
Finally, it should be noted that the above embodiments are intended to illustrate the technical solutions of the present invention and not to limit the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. A prebiotic composition comprising a fructooligosaccharide and a galactooligosaccharide.
2. The prebiotic composition according to claim 1, wherein the fructooligosaccharide is present in an amount of 100 to 900 parts by mass, and the galactooligosaccharide is present in an amount of 100 to 900 parts by mass.
3. The prebiotic composition according to claim 1, wherein the fructooligosaccharide is contained in an amount of 300 to 900 parts by mass and the galactooligosaccharide is contained in an amount of 100 to 700 parts by mass.
4. The prebiotic composition according to claim 1, wherein the fructooligosaccharide is present in an amount of 500 to 900 parts by mass and the galactooligosaccharide is present in an amount of 100 to 500 parts by mass.
5. The prebiotic composition according to claim 1, wherein the fructooligosaccharide is present in an amount of 700 to 900 parts by mass and the galactooligosaccharide is present in an amount of 100 to 300 parts by mass.
6. Use of a prebiotic composition according to any one of claims 1 to 5 in the manufacture of a product for the amelioration of obesity.
7. Use of prebiotic composition according to any one of claims 1 to 5 in the manufacture of a product for lowering serum lipopolysaccharide and serum D-lactic acid.
8. Use of a prebiotic composition according to any one of claims 1 to 5 in the manufacture of a product for reducing weight gain.
9. Use of a prebiotic composition according to any one of claims 1 to 5 in the manufacture of a product for reducing epididymal fat.
10. Use of a prebiotic composition according to any one of claims 1 to 5 in the manufacture of a product for use in the emerging field of micro-ecological medical treatment.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110792547.XA CN113476463A (en) | 2021-07-13 | 2021-07-13 | Prebiotic composition and application thereof |
| PCT/CN2022/105423 WO2023284778A1 (en) | 2021-07-13 | 2022-07-13 | Prebiotic composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110792547.XA CN113476463A (en) | 2021-07-13 | 2021-07-13 | Prebiotic composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476463A true CN113476463A (en) | 2021-10-08 |
Family
ID=77939224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110792547.XA Pending CN113476463A (en) | 2021-07-13 | 2021-07-13 | Prebiotic composition and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113476463A (en) |
| WO (1) | WO2023284778A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023284778A1 (en) * | 2021-07-13 | 2023-01-19 | 量子高科(广东)生物有限公司 | Prebiotic composition and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111838683A (en) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | Prebiotic composition containing human milk oligosaccharide and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2611203T3 (en) * | 2007-12-21 | 2017-05-05 | N.V. Nutricia | Use of sphingomyelin and non-digestible carbohydrates to improve intestinal microbiota |
| CN107198250B (en) * | 2017-05-23 | 2019-03-12 | 北京瑞千景科技发展有限公司 | Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application |
| CN113476463A (en) * | 2021-07-13 | 2021-10-08 | 量子高科(广东)生物有限公司 | Prebiotic composition and application thereof |
-
2021
- 2021-07-13 CN CN202110792547.XA patent/CN113476463A/en active Pending
-
2022
- 2022-07-13 WO PCT/CN2022/105423 patent/WO2023284778A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111838683A (en) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | Prebiotic composition containing human milk oligosaccharide and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| SILVIA FANARO等: "Galacto-oligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: A review", 《ACTA PÆDIATRICA》 * |
| 薛雅莺等: "低聚半乳糖的特性及应用前景", 《发酵科技通讯》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023284778A1 (en) * | 2021-07-13 | 2023-01-19 | 量子高科(广东)生物有限公司 | Prebiotic composition and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023284778A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI391100B (en) | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants | |
| JP4553604B2 (en) | Function enhancing composition for general food, health functional food or health supplement and method thereof | |
| EP3077005B1 (en) | Composition comprising a uridine source and an omega-3 pufa for improving coordination, balance, grip strength or fine motor skills | |
| WO2010048481A1 (en) | Nutritional composition to promote healthy development and growth | |
| TW201236577A (en) | Staged infant feeding regimen to promote healthy development and growth | |
| CN109287920A (en) | A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics | |
| Xiao et al. | Effects of vegetarian diet-associated nutrients on gut microbiota and intestinal physiology | |
| US20160287702A1 (en) | Method of Improving Immune Function in Mammals using Lactobacillus Strains with Certain Lipids | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN114558038B (en) | Probiotic composition for losing weight and reducing fat as well as preparation method and application thereof | |
| CN109393493A (en) | A kind of predigestion type pancebrin of the calcium containing HMB and preparation method thereof | |
| De Cosmi et al. | Fructooligosaccharides: from breast milk components to potential supplements. A systematic review | |
| CN113476463A (en) | Prebiotic composition and application thereof | |
| WO2023176952A1 (en) | Composition for controlling proliferation of bacterium in intestine, and use thereof | |
| CN108936609B (en) | Nutritional preparation for elderly patients with swallowing dysfunction | |
| JP2022508702A (en) | Human dietary supplements and methods for treating digestive and immune system disorders | |
| CN117715540A (en) | Infant formula for feeding infants receiving infant formula and human breast milk | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| CN107518382A (en) | A kind of method for the middle short chain acids abundance for lifting enteron aisle | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| JP2004041006A (en) | Liquid nutrition composition | |
| WO2014163031A1 (en) | Instantaneous intestinal regulator | |
| Utomo et al. | Premature Infants | |
| Pournami et al. | Clinical uses of fructooligosaccharides for gastrointestinal health in the pediatric population | |
| CN118766091A (en) | Application of nutritional composition in improving content of short chain fatty acid in intestinal tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |